Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades

ATRA+ATO combination in APL – A commentary on “evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades” by Teng-Fei et al.

“…To conclude, as clearly shown by Teng-Fei and colleagues [12] , in the real-world setting, ATRA+ATO combination can be beneficial in preventing ED and resulting in superior clinical outcomes. Together with these benefits, this combination can also be more cost-effective when compared to conventional treatment modalities.…”

“…Teng-Fei et al. [12] retrospectively examined the treatment modalities applied to 1105 patients with APL, and a real evaluation was made by taking the data of the last 30 years from the Shanghai Institute of Hematology (SIH) database. By systematically comparing three calendar periods classified by different treatment modalities, the overall trend of treatment development and its real benefits are explained from a real-world perspective.…”

“…A decrease in premature mortality and a lower rate of relapse have been reported due to the introduction of ATO. The dose of cytotoxic chemotherapy appears to decrease over time as a result of the widespread adoption of ATRA and ATO in non-high-risk patients [12] . It has shown that the development of treatment paradigms in APL not only prolongs survival, but also saves patients from the toxicity of intensive chemotherapy.…”

“…In addition, a revised risk scoring model was created for the estimation of OS. It has been stated that a high WBC counts and the presence of NRAS mutations increase the tendency to relapse [12] . Accordingly, a revised predictive model for DFS has been developed that can clearly distinguish patients at higher risk of disease recurrence.…”

“…Accordingly, a revised predictive model for DFS has been developed that can clearly distinguish patients at higher risk of disease recurrence. It has been stated that the development of targeted agents in the chemotherapy process can prevent premature deaths and have positive effects on the treatment of APL patients [12] . It shows that both clinical parameters and molecular markers provide a prognostic value during the ATRA+ATO period and incorporating these indicators into the risk stratification system allows for more accurate estimation of relapse and survival, as well as rapid management of ED risk.…”